Namely, the increase in tumor-associated N-glycan branched structures promotes activation of different RTKs associated with cancer progression, such as the epidermal growth factor receptor (EGFR) [38,39,40], human epidermal growth factor receptor 2 (HER2) [41,42,43] and vascular endothelial growth factor receptor (VEGFR) [44,45]. Here, ERBB2 is linked to cancer.